December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Helus Pharma Inc. - Common Stock (NQ:HELP)

9.030 +0.230 (+2.61%)
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Helus Pharma Inc. - Common Stock

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Guggenheim Healthcare Innovation Conference Nov. 9
Via Investor Brand Network
News headline image
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT 
From Helus Pharma Inc.
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Announces Leadership Transition, Appoints Mark Lawson Independent Board Chair
Via Investor Brand Network
News headline image
Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
From Helus Pharma Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Highlights Phase 3 HLP003 Readout Timeline and Plans for HLP004 Phase 2 Study
Via Investor Brand Network
News headline image
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
From Helus Pharma Inc.
Via GlobeNewswire
News headline image
Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances ↗
Cybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth... 
Via MarketBeat
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints CNS Drug Development Veteran Suresh Durgam to Board of Directors
Via Investor Brand Network
News headline image
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
From Helus Pharma Inc.
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Host Investor Presentation Highlighting Depression and Anxiety Treatment Programs on Oct. 21
Via Investor Brand Network
News headline image
Helus Pharma to Host Investor Presentation on October 21, 2026
From Helus Pharma Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Changes Legal Name from Cybin Inc.
Via Investor Brand Network
News headline image
Helus Pharma Announces Completion of Legal Name Change
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression ↗
Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of... 
Via MarketBeat
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Annual and Special Meeting Results, Legal Name Change Effective Oct. 1
Via Investor Brand Network
News headline image
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
From Helus Pharma
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in TD Cowen Neuropsychiatry Summit
Via Investor Brand Network
News headline image
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board ↗
Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor,... 
Via MarketBeat
News headline image
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT 
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Presents HLP003 Data From MDD Program at Psych Congress 2026
Via Investor Brand Network
News headline image
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 ↗
Cybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global... 
Via MarketBeat
News headline image
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances ↗
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter,... 
Via MarketBeat
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. 
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT 
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Cantor Global Healthcare Conference
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. 
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.